Home » Basilea Shares Drop as Zevtera Approval Is Delayed
Basilea Shares Drop as Zevtera Approval Is Delayed
Shares of Basilea Pharmaceutica dropped after the Swiss drugmaker saw approval for a skin-infection drug delayed, and the company filed an arbitration claim against Johnson & Johnson.
MarketWatch
MarketWatch
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May